[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 14th that it has obtained a manufacturing license for advanced biopharmaceuticals from the Ministry of Food and Drug Safety and will enter the contract development and manufacturing organization (CDMO) business.
Based on this license, Daewoong Pharmaceutical will start an "all-in-one package" business encompassing manufacturing of advanced biopharmaceuticals including cell therapy products, development, quality testing, regulatory support, storage and delivery, and sales.
The company plans to provide its cell therapy production technology, pharmaceutical sales, and marketing services that meet global standards to partner companies under cooperation agreements.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
